Adjuvant trastuzumab for breast cancer: Uncertainties in clinical and economic evidence following early stopping of the HERA trial

Tallal Younis; Chris Skedgel

doi:10.2165/11588350-000000000-00000

Adjuvant trastuzumab for breast cancer: Uncertainties in clinical and economic evidence following early stopping of the HERA trial

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	361-365
Number of pages	5
Journal	PharmacoEconomics
Volume	29
Issue number	5
DOIs	https://doi.org/10.2165/11588350-000000000-00000
Publication status	Published - May 2011

Keywords

Antibodies
Monoclonal, Humanized
Antineoplastic Agents
Breast Neoplasms
Chemotherapy
Cost-Benefit Analysis
Disease-Free Survival
Early Termination of Clinical Trials
Female
Humans
Randomized Controlled Trials as Topic

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2165/11588350-000000000-00000

Cite this

@article{81f50b2a2cf84502bcdc84610e8839d3,

title = "Adjuvant trastuzumab for breast cancer: Uncertainties in clinical and economic evidence following early stopping of the HERA trial",

keywords = "Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Breast Neoplasms, Chemotherapy, Cost-Benefit Analysis, Disease-Free Survival, Early Termination of Clinical Trials, Female, Humans, Randomized Controlled Trials as Topic",

author = "Tallal Younis and Chris Skedgel",

year = "2011",

month = may,

doi = "10.2165/11588350-000000000-00000",

language = "English",

volume = "29",

pages = "361--365",

journal = "PharmacoEconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "5",

}

TY - JOUR

T1 - Adjuvant trastuzumab for breast cancer

T2 - Uncertainties in clinical and economic evidence following early stopping of the HERA trial

AU - Younis, Tallal

AU - Skedgel, Chris

PY - 2011/5

Y1 - 2011/5

KW - Antibodies

KW - Monoclonal, Humanized

KW - Antineoplastic Agents

KW - Breast Neoplasms

KW - Chemotherapy

KW - Cost-Benefit Analysis

KW - Disease-Free Survival

KW - Early Termination of Clinical Trials

KW - Female

KW - Humans

KW - Randomized Controlled Trials as Topic

U2 - 10.2165/11588350-000000000-00000

DO - 10.2165/11588350-000000000-00000

M3 - Article

C2 - 21504237

VL - 29

SP - 361

EP - 365

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 5

ER -